For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL1835Ma&default-theme=true
RNS Number : 1835M Bank of America Merrill Lynch 12 September 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
Date of dealing 11/09/2023
BofA Securities, Inc.
Company dealt in
HORIZON THERAPEUTICS PLC
Class of relevant security to which the
dealings being disclosed relate(Note 1)
Common - IE00BQPVQZ61
Date of dealing
11/09/2023
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
Number % Number %
(1) Relevant securities 376,025 0.164% 134,489 0.059%
(2) Derivatives (other than options): 166,865 0.073% 60,931 0.027%
(3) Options and agreements to purchase/sell: 50,000 0.022% 19,500 0.009%
Total 592,890 0.259% 214,920 0.094%
376,025
0.164%
134,489
0.059%
(2) Derivatives (other than options):
166,865
0.073%
60,931
0.027%
(3) Options and agreements to purchase/sell:
50,000
0.022%
19,500
0.009%
Total
592,890
0.259%
214,920
0.094%
(b) Interests and short positions in relevant securities of the company, other
than the
class dealt in (Note 2)
Class of relevant security:
Long Short
Number % Number %
(1) Relevant securities 0 0% 0 0%
(2) Derivatives (other than options): 0 0% 0 0%
(3) Options and agreements to purchase/sell: 0 0% 0 0%
Total 0 0% 0 0%
0
0%
0
0%
(2) Derivatives (other than options):
0
0%
0
0%
(3) Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 9,000 114.15 USD
Purchase 5,000 114.7 USD
Purchase 1,524 114.75 USD
Purchase 3,800 114.795 USD
Purchase 1,200 114.8 USD
Purchase 700 114.803 USD
Purchase 100 114.805 USD
Purchase 4,200 114.81 USD
Purchase 71 114.97 USD
Purchase 400 114.995 USD
Purchase 4,529 115 USD
Purchase 1,700 115.045 USD
Purchase 3,300 115.05 USD
Purchase 1,500 115.078 USD
Purchase 700 115.08 USD
Purchase 12,800 115.1 USD
Purchase 5,000 115.255 USD
Purchase 3 115.28 USD
Purchase 1 115.29 USD
Purchase 3 115.3 USD
Purchase 6 115.32 USD
Purchase 1 115.34 USD
Purchase 50,009 115.35 USD
Purchase 9 115.36 USD
Purchase 12 115.37 USD
Purchase 6 115.38 USD
Purchase 14 115.42 USD
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 3,873 113.7 USD
Sale 64 113.71 USD
Sale 1,100 113.73 USD
Sale 2 113.74 USD
Sale 1,035 113.75 USD
Sale 161 113.76 USD
Sale 6,436 113.8 USD
Sale 98 113.81 USD
Sale 1,209 113.82 USD
Sale 286 113.84 USD
Sale 4,132 113.85 USD
Sale 1,102 113.86 USD
Sale 269 113.87 USD
Sale 8,873 113.9 USD
Sale 1,700 113.91 USD
Sale 1,939 113.94 USD
Sale 28,511 113.95 USD
Sale 182 113.96 USD
Sale 1,400 113.97 USD
Sale 20,090 113.98 USD
Sale 69,441 114 USD
Sale 4,836 114.01 USD
Sale 312 114.02 USD
Sale 4 114.04 USD
Sale 60 114.06 USD
Sale 2,000 114.66 USD
Sale 82 114.67 USD
Sale 1,375 114.7 USD
Sale 200 114.71 USD
Sale 24,802 114.75 USD
Sale 200 114.755 USD
Sale 200 114.76 USD
Sale 200 114.765 USD
Sale 200 114.768 USD
Sale 2,900 114.77 USD
Sale 3,107 114.775 USD
Sale 500 114.785 USD
Sale 100 114.795 USD
Sale 6,703 114.8 USD
Sale 3,890 114.805 USD
Sale 5,000 114.809 USD
Sale 300 114.81 USD
Sale 200 114.815 USD
Sale 5,000 114.825 USD
Sale 2,800 114.85 USD
Sale 1,200 114.9 USD
Sale 7 114.966 USD
Sale 10,000 115.095 USD
Sale 1 115.42 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 5) (Note 6)
(Note 4)
Swaps Increasing a Long Position 41 114.75 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc Expiry date Option money paid/ received per unit (Note 4)
N/A N/A N/A N/A N/A N/A N/A
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option
unit (Note 4)
N/A N/A N/A
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7)
(if applicable) (Note 4)
N/A N/A N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights
or future acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 12/09/2023
Contact name Frank Lui
Telephone number +44207 996 6418
Name of offeree/offeror with which connected AMGEN INC
Nature of connection (Note 9) Advisor to - AMGEN INC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPEAENAFLEDEFA